A

AstraZeneca

Global pharmaceutical company developing prescription medicines

Engineering Director - AI Solutions, Enabling Functions

Full-TimePosted on 10/1/2026Deadline 10/8/26
No salary listed
Expert
Barcelona, Spain
In Person

About the job

Requirements
  • Significant demonstrated experience building AI applications within a large, regulated enterprise.
  • Demonstrated experience delivering AI solutions across multiple enabling functions, such as HR, Finance, Procurement, Legal, and Audit.
  • Significant experience governing AI systems and embedding operational resilience disciplines around them.
  • Ability to treat regulatory requirements as architecture decisions.
  • Significant experience designing AI governance frameworks, building governance tooling, and operating in governance roles.
  • Significant hands-on engineering delivery experience in operational resilience.
Responsibilities
  • Lead the engineering roadmap for AI across enabling functions, aligning architecture, delivery sequencing, and capability development to business priorities across HR, Finance, Procurement, Legal, Audit, and Compliance.
  • Set architectural direction for scalable, governed AI platforms, designing for modularity, cross-functional reuse, and compliance from the outset.
  • Make high-consequence technical decisions on architecture, build-versus-buy, model strategy (foundation models, fine-tuning, multi-provider orchestration, and retrieval-augmented generation), and integration patterns.
  • Drive platform thinking over project thinking by building shared components, reusable agent patterns, and common governance instrumentation that accelerate delivery across the portfolio.
  • Ensure architecture accounts for data sovereignty through model routing, data residency, and hosting decisions that respect jurisdictional boundaries and cross-border transfer requirements.
  • Shape investment cases for senior stakeholders, articulating engineering decisions in terms of scalability, risk, regulatory defensibility, and value creation.
  • Design and ship multi-agent large language model architectures across multiple model providers, choosing models against product requirements and compliance constraints, including sovereignty-aware routing through region-specific infrastructure where required.
  • Build retrieval-augmented generation pipelines over real enterprise corpora with named single-purpose agents, hallucination guards before user-facing output, and immutable audit logging at every stage.
  • Use AI-assisted development tooling to compress delivery from months to days while keeping architecture decisions, model routing, and guardrails under deliberate human control.
  • Lead technical design for complex solutions across enabling functions, including HR policy automation, contract risk scoring, procurement analytics, compliance monitoring, financial forecasting, audit analytics, and document intelligence, with governance built in from the first build.
  • Ensure rapid experimentation capability with clear engineering gates between proof-of-concept, pilot, and production, measuring against real data and real success criteria rather than mock demonstrations.
  • Design and operate governance structures surrounding AI applications, including classification and tiering, risk assessment, model registration, approval workflows, ongoing monitoring obligations, and decommissioning criteria.
  • Ensure systems meet requirements under applicable data protection laws, AI-specific regulations (including EU AI Act risk classification and emerging national AI frameworks), and sector-specific operational resilience expectations, navigating regulatory divergence across jurisdictions.
  • Design data-residency and model-routing approaches that respect adequacy arrangements, data-transfer mechanisms, and sovereignty constraints, ensuring processing is separated by jurisdiction where required and providing sovereign model options such as region-specific cloud deployments or local model hosting.
  • Design agentic systems where consequential autonomous actions are human-gated and every decision writes an audit row recording what model decided what, and on what evidence.
  • Embed deterministic classification and routing layers, human-in-the-loop oversight, model and data cards, and full audit trails into standard engineering practice.
  • Ensure governance tooling supports independent review and maintains separation between the teams that build and the functions that assess, with tool design reflecting this control.
  • Ensure systems handling financially material data, legally privileged documents, employee-sensitive information, supplier-confidential data, or audit evidence meet relevant governance and evidential standards, including SOX, legal privilege, chain-of-custody, and employment law.
  • Own ongoing governance obligations for live AI systems, including periodic reassessment, performance review against stated tolerances, change-impact assessment, and documented decision trails for model updates or retirement.
  • Engineer operational resilience into AI applications using circuit breakers, provider fallbacks, graceful degradation, fail-safe defaults, and dependency-aware architecture so essential functions survive outages.
  • Design for failure by assuming model providers, data sources, and integration points will fail, and ensuring user-facing services degrade safely rather than catastrophically.
  • Map AI systems against the organisation's important business services framework, with defined impact tolerances, recovery objectives, and tested failover paths.
  • Lead a multidisciplinary engineering team comprising software, machine learning, data, and platform engineers, recruiting, developing, and retaining strong technical talent.
  • Set engineering culture and standards for code quality, testing, documentation, peer review, and production readiness.
  • Develop senior technical contributors and engineering leads, building depth and succession within the team.
  • Mentor and enable non-technical colleagues across enabling functions to ship their own AI applications, building AI literacy across HR, Finance, Procurement, Legal, Audit, and Compliance.
  • Manage capacity and team topology by making deliberate choices about structure, specialisation, and balance across discovery, delivery, and sustainment.
  • Drive end-to-end engineering delivery from architecture through production deployment, scaling, monitoring, and lifecycle management.
  • Partner with enterprise technology teams to leverage shared platforms, infrastructure, and services, ensuring solutions are built on common foundations and contribute to enterprise capability.
  • Establish and enforce standards for model serving, data pipelines, API design, integration patterns, security, and observability.
  • Drive MLOps maturity, including continuous integration and continuous delivery, automated testing, performance monitoring, incident management, and capacity planning.
  • Own the data engineering approach for AI across enabling functions, including pipelines, feature stores, and data products designed for quality, governance, and reuse.
  • Establish data quality, lineage, and governance standards appropriate for financially material data, legally privileged documents, employee personally identifiable information, and personal data subject to applicable data protection laws.
  • Establish model-drift and bias monitoring across the portfolio, measuring divergence across runs and generating targeted refinement recommendations.
  • Design and operate AI red-team capability to probe and refine model outputs before release and on an ongoing basis.
  • Build automated fairness testing, explainability pipelines, and decision audit trails embedded in standard workflows.
  • Own technical risk management across the portfolio, including model degradation, data quality drift, dependency risk, and integration risk.
  • Ensure model assurance reporting meets the expectations of internal audit, technology governance, and external regulators.
  • Work in close partnership with enterprise technology to align on shared infrastructure, platform services, tooling, and engineering standards.
  • Identify and scale opportunities across enabling functions, adapting solutions proven in one function for deployment in another.
  • Engage external technology partners strategically, co-developing or integrating capabilities where they accelerate delivery or provide specialist functionality.
  • Shape joint programmes with partners by defining technical scope, integration architecture, and quality standards, ensuring partnerships deliver production-grade outcomes.
  • Build a scaling model leveraging shared services, external partners, and cross-functional reuse to multiply impact without proportional headcount growth.
  • Serve as a credible technical partner to functional leaders across HR, Finance, Procurement, Legal, Audit, and Compliance, providing counsel on AI opportunity, risk, regulatory posture, and investment.
  • Run discovery with each business unit, surface real problems, frame concrete use cases with measurable success criteria, and drive adoption through continuous user-experience iteration and direct user-feedback loops.
  • Translate engineering complexity and business strategy by communicating trade-offs, timelines, and constraints so leaders can make informed decisions.
  • Measure success by real adoption and operational impact, building key performance indicator and key risk indicator frameworks that give leaders visibility into usage, quality, and value.
  • Represent enabling functions within enterprise AI leadership forums and architecture governance, ensuring alignment on standards, platform strategy, and shared services.
  • Contribute to enterprise AI governance through architecture review boards, AI policy development, and standards evolution.
  • Drive reuse and knowledge sharing by identifying where governance and resilience patterns developed for enabling functions can accelerate delivery elsewhere.
  • Advocate for enabling-function requirements within the broader enterprise technology agenda, ensuring platform priorities reflect the needs of regulated, process-critical functions.

About the company

AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Get referred to AstraZeneca

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sept. 29, 2026 FDA filing for Orpathys-Tagrisso targets EGFR-mutated MET-overexpressing lung cancer.
  • Oct. 2026 Medicare-negotiation appeal keeps AstraZeneca fighting for U.S. pricing power.
  • July 2026 Tagrisso appellate win preserved a blockbuster and validated its patent moat.

What critics are saying

  • Forxiga patents face France, Portugal, and Poland challenges, with an October 2026 trial.
  • Lynparza faces Canadian generics in October 2026, threatening near-term ovarian-cancer revenue.
  • Tagrisso and Forxiga patent losses would puncture AstraZeneca's cash engines before 2027.

What makes AstraZeneca unique

  • Sept. 28, 2026 Summit deal extends AstraZeneca's ADC leadership into PD-1/VEGF combinations.
  • July 2026 CLARITY-Gastric01 strengthened sonesitatug vedotin, reinforcing AstraZeneca's GI oncology franchise.
  • Sept. 25, 2026 baxdrostat registration shows durable cardiovascular depth beyond oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

↑ 6%

1 year growth

↑ 6%

2 year growth

↑ 9%
MedCity News
Sep 29th, 2026
AstraZeneca places a $2B bet on a Summit Therapeutics cancer drug.

AstraZeneca places a $2B bet on a Summit Therapeutics cancer drug. AstraZeneca's equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical companies testing the pairing of antibody drug conjugates with PD-1/VEGF bispecific antibodies, a drug combination that could offer advantages in cancer treatment. By Frank Vinluan on September 29, 2026 3:25 pm AstraZeneca is making a $2 billion equity investment in Summit Therapeutics, a business deal that also kicks off a research collaboration that could pursue multiple drug combinations with an initial focus on gastrointestinal cancers. The deal announced after Monday's market close is a vote of confidence in the Summit cancer drug ivonescimab, a bispecific antibody designed to bind to two targets, PD-1 on T cells and VEGF on cancer cells. Several oncology-focused pharmaceutical companies have already struck deals to add such drugs to their pipelines. Summit's late-clinical drug gives AstraZeneca access to a contender in the class. Ivonescimab was developed by China-based Akeso Therapeutics. Phase 3 trial results in lung cancer raised hopes for the molecule as data showed it beat Merck's blockbuster PD-1 inhibitor Keytruda in a head-to-head study. But those results were from a trial in China, where the drug has approvals in lung cancers and is marketed by Akeso. For Summit, ivonescimab's prospects ride on the results of clinical trials the company is conducting in outside of China. Summit holds rights to the drug in North and South America, Europe, the Middle East, Africa, and Japan. We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey. AstraZeneca is a leader in the development and commercialization of antibody drug conjugates (ADCs) for cancer. The Summit deal gives AstraZeneca the opportunity to test its experimental ADC sonesitatug vedotin (sone-ve) in combination with ivonescimab. In July, AstraZeneca reported sone-ve led to statistically significant improvement in overall survival, meeting the main goal of a Phase 3 test in CLDN18.2-positive gastric cancers. Detailed trial results are scheduled for presentation at the upcoming European Society for Medical Oncology conference in late October. This medical meeting will also include the presentation of data for ivonescimab in biliary tract cancer. Last month, Summit reported preliminary Phase 3 results showing statistically significant improvement. This pivotal study was conducted by Akeso in China. Drug resistance is one limitation of ADCs, but PD-1/VEGF bispecific antibodies may be able to help. In addition to bringing two distinct approaches to cancer, the dual mechanism also makes the tumor microenvironment more favorable to ADCs, which is hoped to overcome resistance. The potential advantages of combining PD-(L)1/VEGF bispecific antibodies with an ADC has led to a flurry of dealmaking to explore such drug pairings. AbbVie, Bristol Myers Squibb, Merck, Pfizer, and have struck business deals for bispecific antibodies in this class. Biotech companies are also striking deals. Late last year, Crescent Biopharma licensed a Kelun Biopharma ADC it plans to test in combination with its PD-1/VEGF bispecific antibody. AstraZeneca's new collaboration could extend beyond sone-ve. The Summit deal includes a non-binding memorandum of understanding that permits additional clinical trials testing ivonescimab in combination with other AstraZeneca cancer drugs, including other ADCs. presented by We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring. "A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumor types with combinations alongside next-generation immunotherapies," Susan Galbraith, AstraZeneca executive vice president, oncology hematology R&D, said in a prepared statement. AstraZeneca's Summit investment lends additional validation to the class of bispecific PD-(L)1/VEGF antibodies, Leerink Partners analyst Daina Graybosch said in a research note. But she also characterized the deal as "more tepid than an outright acquisition," adding that while the collaboration may lead AstraZeneca to invest more in Summit, it's also possible the pharma company learns from the trials and then licenses a competing drug in the class. That strategy has precedent. Graybosch pointed to a TROP2-targeting ADC that Merck licensed from Kelun. The deal happened after Merck reviewed data from clinical trials it conducted in collaboration with AstraZeneca and Gilead Sciences. Astrazeneca's agreement with Summit calls for the pharma company to buy about 108,955 shares of its new partner for $18.36 each, representing an 18.6% premium over Monday's closing stock price. The companies will jointly contribute to the costs of the planned clinical trials, which they expect will be sponsored by AstraZeneca. Each company also retains development and commercialization rights to its respective molecules. The deal is expected to close by the end of this week.

Affärsvärlden
Sep 29th, 2026
AstraZeneca seeks US approval for lung cancer combination.

AstraZeneca seeks US approval for lung cancer combination. The pharmaceutical company AstraZeneca has submitted an application to the FDA for approval of Orpathys in combination with Tagrisso for locally advanced or metastatic EGFR-mutated lung cancer with MET overexpression or amplification after prior EGFR-directed treatment. Today 11:15 This is stated in a press release from the partner Hutchmed. The application is supported by the phase 3 study SAFFRON, in which the combination improved both progression-free and overall survival compared with platinum-based doublet chemotherapy. Orpathys (with the active substance savolitinib) is being developed jointly through a global collaboration between AstraZeneca and Hutchmed. AstraZeneca 1,677.50 SEK +1.64% (+27.0 SEK)

AstraZeneca
Sep 28th, 2026
AstraZeneca invests $2B in Summit Therapeutics to advance cancer ADC combination strategy

AstraZeneca has announced a $2 billion equity investment in Summit Therapeutics to advance cancer treatment combinations. The investment will give AstraZeneca approximately 12% of Summit's outstanding common stock. The companies have entered a clinical collaboration to evaluate sonesitatug vedotin, a Claudin-18.2 antibody drug conjugate, combined with ivonescimab, a bispecific antibody targeting PD-1 and VEGF, in gastrointestinal cancers. Trials are set to begin imminently. Each company will retain development and commercial rights to their respective medicines whilst jointly contributing to trial costs. The collaboration aims to broaden AstraZeneca's ADC portfolio across multiple tumour types. AstraZeneca recently reported positive results from the CLARITY-Gastric01 trial for sonesitatug vedotin in advanced gastric cancers, with results to be presented at a 2026 medical congress.

MarketScreener
Sep 28th, 2026
Summit Therapeutics Inc. and astrazeneca enter into clinical trial collaboration to evaluate ivonescimab in combination with sonesitatug vedotin in multiple gastrointestinal cancers.

Summit Therapeutics Inc. and astrazeneca enter into clinical trial collaboration to evaluate ivonescimab in combination with sonesitatug vedotin in multiple gastrointestinal cancers. Published on 09/28/2026 at 05:30 pm EDT S&P Capital IQ Summit Therapeutics Inc. entered into a clinical collaboration agreement with AstraZeneca to evaluate sonesitatug vedotin in combination with ivonescimab with the intent to start studies in certain gastrointestinal (GI) cancer settings imminently. Under the terms of the clinical collaboration agreement, each company will contribute their respective compound for the combination studies to be conducted, and the parties will jointly contribute to the costs of such studies, which are intended to be sponsored by AstraZeneca. Each company will retain development and commercial rights to their respective molecules. Moreover, Summit and AstraZeneca intend to evaluate ivonescimab with an additional set of AstraZeneca?s cancer medicines, including other antibody drug conjugates (ADCs). The companies intend to share clinical development costs of potential future studies. Each company will retain their current development and commercial rights to their respective molecules, and the agreement is mutually non-exclusive. There are no additional financial considerations associated with milestones, royalties, revenue-sharing, or profit-sharing. The Memorandum of Understanding with respect to the potential clinical trial collaboration between Summit and AstraZeneca is non-binding, and there can be no assurances that the intended clinical trial collaboration comes to fruition. (C) S&P Capital IQ - 2026

University of Arkansas for Medical Sciences
Sep 25th, 2026
College of Pharmacy recognized at national convention.

College of Pharmacy recognized at national convention. By Benjamin Waldrum Sept. 25, 2026 | The UAMS College of Pharmacy's student chapter of the Student National Pharmaceutical Association (SNPhA) received an award at its annual convention in August, and several pharmacy students were recognized with individual honors. SNPhA is the official student association of the National Pharmaceutical Association (NPhA). Goodlow posing with a placard listing her as a candidate for public relations liaison, for which she was later elected. This year, the UAMS student chapter received an award for 20% membership growth, notable for a smaller chapter. This year's delegates were third-year students Lynn Duncan, Marissa Bones, Ma'Kyah Goodlow, and Mackenzie Rodgers, along with second-year students Tykia Rankin and Bryce Piper-Eason. "It was an incredible experience," Goodlow said. "We all had a wonderful time networking, learning, and representing UAMS on the national stage." Goodlow was elected as the SNPhA national public relations liaison and was a finalist in AstraZeneca's Medical Science Liaison competition. Goodlow, Duncan, and Piper-Eason participated in the CVS Health Leadership Academy. Rodgers was nominated to serve on the Nominations Committee next year, which helps select and vet key leadership positions. "I am incredibly proud to see our students recognized nationally," said Kendrea Jones, Pharm.D., the chapter's co-advisor. "Their accomplishments reflect the mission of SNPhA to support the professional development of pharmacy students while improving the health of underserved communities. These students have demonstrated leadership, professional growth and a commitment to service throughout the year, and their national recognition is a wonderful reflection of their hard work and the strength of our UAMS chapter." Rodgers, the chapter president this year, worked alongside representatives from around the country to vet candidates for the SNPhA National Executive Board, including candidates from Region 4, which includes Arkansas. "I am incredibly blessed and grateful to serve on this committee engaging with the future pharmacists of the nation," Rodgers said. "I'm thankful for the many connections made at the conference and highly encourage students to take any opportunity to attend a conference at least once throughout your academic career - you never know who you will meet."